Loading
A phase 1 trial of KTX-2001 run by K36 Therapeutics, Inc., now recruiting.
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001) is a phase 1 interventional study registered as NCT07103018 by K36 Therapeutics, Inc., with 144 participants planned, started 2025-11-21. Conditions recorded: Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer Patients, Metastatic Castration-resistant Prostate Cancer, mCRPC, mCRPC and mCRPC (Metastatic Castration-resistant Prostate Cancer). Interventions recorded: KTX-2001 and KTX-2001 + Darolutamide (NUBEQA®).
Shares K36 Therapeutics and the tag pipeline.
Shares K36 Therapeutics and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/